Literature DB >> 25967227

Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers.

Saskia Koene1, Paul de Laat2, Doorlène H van Tienoven3, Gert Weijers4, Dennis Vriens4, Fred C G J Sweep3, Janneke Timmermans5, Livia Kapusta6,7, Mirian C H Janssen2,8, Jan A M Smeitink2.   

Abstract

In this observational cohort study, we examined the prognostic value of growth and differentiation factor 15 (GDF15) in indicating and monitoring general mitochondrial disease severity and progression in adult carriers of the m.3243A>G mutation.Ninety-seven adult carriers of the m.3243A>G mutation were included in this study. The Newcastle mitochondrial disease adult scale was used for rating mitochondrial disease severity. In parallel, blood was drawn for GDF15 analysis by ELISA. Forty-nine carriers were included in a follow-up study. In a small subset of subjects of whom an echocardiogram was available from general patient care, myocardial deformation was assessed using two-dimensional speckle-tracking strain analysis.A moderate positive correlation was found between the concentration of GDF15 and disease severity (r = 0.59; p < 0.001). The concentration of serum GDF15 was higher in m.3243A>G carriers with diabetes mellitus, cardiomyopathy, and renal abnormalities. After a 2-year follow-up, no significant correlation was found between the change in disease severity and the change in the concentration of GDF15 or between the GDF15 level at the first assessment and the change in disease severity. In the subcohort of patients of whom an echocardiogram was available, the concentration of GDF15 correlated moderately to longitudinal global strain (r = 0.55; p = 0.006; n = 23) but not to circumferential or radial strain.Our results indicate that serum GDF15 is not a strong surrogate marker for general mitochondrial disease severity. Its value in indicating myocardial deformation should be confirmed in a prospective longitudinal study.

Entities:  

Year:  2015        PMID: 25967227      PMCID: PMC4582022          DOI: 10.1007/8904_2015_436

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  27 in total

1.  Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease.

Authors:  Samuel N Breit; Juan J Carrero; Vicky Wang-Wei Tsai; Nasreen Yagoutifam; Wei Luo; Tamara Kuffner; Asne R Bauskin; Liyun Wu; Lele Jiang; Peter Barany; Olof Heimburger; Mary-Ann Murikami; Fred S Apple; Christopher P Marquis; Laurence Macia; Shu Lin; Amanda Sainsbury; Herbert Herzog; Matthew Law; Peter Stenvinkel; David A Brown
Journal:  Nephrol Dial Transplant       Date:  2011-09-22       Impact factor: 5.992

2.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

3.  Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction.

Authors:  Yasuhiro Izumiya; Shinsuke Hanatani; Yuichi Kimura; Seiji Takashio; Eiichiro Yamamoto; Hiroaki Kusaka; Takanori Tokitsu; Taku Rokutanda; Satoshi Araki; Kenichi Tsujita; Tomoko Tanaka; Megumi Yamamuro; Sunao Kojima; Shinji Tayama; Koichi Kaikita; Seiji Hokimoto; Hisao Ogawa
Journal:  Can J Cardiol       Date:  2013-12-18       Impact factor: 5.223

Review 4.  Renal complications in a patient with A-to-G mutation of mitochondrial DNA at the 3243 position of leucine tRNA.

Authors:  Motoharu Hirano; Konosuke Konishi; Naoko Arata; Masahiro Iyori; Takayuki Saruta; Shigeru Kuramochi; Masashi Akizuki
Journal:  Intern Med       Date:  2002-02       Impact factor: 1.271

Review 5.  Biomarkers for mitochondrial respiratory chain disorders.

Authors:  Anu Suomalainen
Journal:  J Inherit Metab Dis       Date:  2010-10-13       Impact factor: 4.982

6.  Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support.

Authors:  Sjoukje I Lok; Bjorn Winkens; Roel Goldschmeding; Ankie J P van Geffen; Fay M A Nous; Joyce van Kuik; Petra van der Weide; Corinne Klöpping; J Hans Kirkels; Jaap R Lahpor; Pieter A Doevendans; Nicolaas de Jonge; Roel A de Weger
Journal:  Eur J Heart Fail       Date:  2012-07-26       Impact factor: 15.534

7.  Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation.

Authors:  Paul de Laat; Saskia Koene; Lambert P W J van den Heuvel; Richard J T Rodenburg; Mirian C H Janssen; Jan A M Smeitink
Journal:  J Inherit Metab Dis       Date:  2012-03-09       Impact factor: 4.982

8.  Cardiomyopathy is common in patients with the mitochondrial DNA m.3243A>G mutation and correlates with mutation load.

Authors:  Kieren G Hollingsworth; Grainne S Gorman; Michael I Trenell; Robert McFarland; Robert W Taylor; Douglass M Turnbull; Guy A MacGowan; Andrew M Blamire; Patrick F Chinnery
Journal:  Neuromuscul Disord       Date:  2012-04-17       Impact factor: 4.296

9.  Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome.

Authors:  Tibor Kempf; Kai C Wollert
Journal:  Crit Care       Date:  2013-07-31       Impact factor: 9.097

10.  Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers.

Authors:  Matthew G D Bates; Kieren G Hollingsworth; Jane H Newman; Djordje G Jakovljevic; Andrew M Blamire; Guy A MacGowan; Bernard D Keavney; Patrick F Chinnery; Douglass M Turnbull; Robert W Taylor; Michael I Trenell; Grainne S Gorman
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-11-04       Impact factor: 6.875

View more
  18 in total

1.  Growth Differentiation Factor 15 Is a Novel Diagnostic Biomarker of Mitochondrial Diseases.

Authors:  Xinbo Ji; Lizhen Zhao; Kunqian Ji; Yuying Zhao; Wei Li; Rui Zhang; Ying Hou; Jianqiang Lu; Chuanzhu Yan
Journal:  Mol Neurobiol       Date:  2016-11-26       Impact factor: 5.590

2.  GDF-15 Is Elevated in Children with Mitochondrial Diseases and Is Induced by Mitochondrial Dysfunction.

Authors:  Raquel Montero; Delia Yubero; Joan Villarroya; Desiree Henares; Cristina Jou; Maria Angeles Rodríguez; Federico Ramos; Andrés Nascimento; Carlos Ignacio Ortez; Jaume Campistol; Belen Perez-Dueñas; Mar O'Callaghan; Mercedes Pineda; Angeles Garcia-Cazorla; Jaume Colomer Oferil; Julio Montoya; Eduardo Ruiz-Pesini; Sonia Emperador; Marija Meznaric; Laura Campderros; Susana G Kalko; Francesc Villarroya; Rafael Artuch; Cecilia Jimenez-Mallebrera
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

3.  A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases.

Authors:  Ryan L Davis; Christina Liang; Carolyn M Sue
Journal:  Neurology       Date:  2016-04-27       Impact factor: 9.910

4.  Is 2D speckle tracking echocardiography useful for detecting and monitoring myocardial dysfunction in adult m.3243A>G carriers? - a retrospective pilot study.

Authors:  S Koene; J Timmermans; G Weijers; P de Laat; C L de Korte; J A M Smeitink; M C H Janssen; L Kapusta
Journal:  J Inherit Metab Dis       Date:  2017-01-04       Impact factor: 4.982

5.  Reduced oxidative capacity in macrophages results in systemic insulin resistance.

Authors:  Saet-Byel Jung; Min Jeong Choi; Dongryeol Ryu; Hyon-Seung Yi; Seong Eun Lee; Joon Young Chang; Hyo Kyun Chung; Yong Kyung Kim; Seul Gi Kang; Ju Hee Lee; Koon Soon Kim; Hyun Jin Kim; Cuk-Seong Kim; Chul-Ho Lee; Robert W Williams; Hail Kim; Heung Kyu Lee; Johan Auwerx; Minho Shong
Journal:  Nat Commun       Date:  2018-04-19       Impact factor: 14.919

6.  Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: A meta-analysis.

Authors:  Yan Lin; Kunqian Ji; Xiaotian Ma; Shuangwu Liu; Wei Li; Yuying Zhao; Chuanzhu Yan
Journal:  Ann Clin Transl Neurol       Date:  2020-06-25       Impact factor: 4.511

7.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

8.  Plasma Gelsolin Reinforces the Diagnostic Value of FGF-21 and GDF-15 for Mitochondrial Disorders.

Authors:  Ana Peñas; Miguel Fernández-De la Torre; Sara Laine-Menéndez; David Lora; María Illescas; Alberto García-Bartolomé; Montserrat Morales-Conejo; Joaquín Arenas; Miguel A Martín; María Morán; Cristina Domínguez-González; Cristina Ugalde
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 9.  Mitochondrial disorders in children: toward development of small-molecule treatment strategies.

Authors:  Werner Jh Koopman; Julien Beyrath; Cheuk-Wing Fung; Saskia Koene; Richard J Rodenburg; Peter Hgm Willems; Jan Am Smeitink
Journal:  EMBO Mol Med       Date:  2016-04-01       Impact factor: 12.137

Review 10.  Monitoring clinical progression with mitochondrial disease biomarkers.

Authors:  Hannah E Steele; Rita Horvath; Jon J Lyon; Patrick F Chinnery
Journal:  Brain       Date:  2017-10-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.